Alector (ALEC) Competitors $3.21 -0.10 (-3.02%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.60 -1.62 (-50.31%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. TRML, NBTX, MAZE, ARDX, CVAC, IMTX, SANA, PGEN, CALT, and NUVBShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Tourmaline Bio (TRML), Nanobiotix (NBTX), Maze Therapeutics (MAZE), Ardelyx (ARDX), CureVac (CVAC), Immatics (IMTX), Sana Biotechnology (SANA), Precigen (PGEN), Calliditas Therapeutics AB (publ) (CALT), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Alector vs. Its Competitors Tourmaline Bio Nanobiotix Maze Therapeutics Ardelyx CureVac Immatics Sana Biotechnology Precigen Calliditas Therapeutics AB (publ) Nuvation Bio Alector (NASDAQ:ALEC) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations. Does the media refer more to ALEC or TRML? In the previous week, Alector had 12 more articles in the media than Tourmaline Bio. MarketBeat recorded 14 mentions for Alector and 2 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.47 beat Alector's score of -0.19 indicating that Tourmaline Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Tourmaline Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, ALEC or TRML? Tourmaline Bio has lower revenue, but higher earnings than Alector. Tourmaline Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$100.56M3.23-$119.05M-$1.16-2.77Tourmaline BioN/AN/A-$73.21M-$3.43-13.97 Which has more risk and volatility, ALEC or TRML? Alector has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Is ALEC or TRML more profitable? Tourmaline Bio has a net margin of 0.00% compared to Alector's net margin of -142.10%. Tourmaline Bio's return on equity of -30.50% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-142.10% -112.06% -26.37% Tourmaline Bio N/A -30.50%-29.63% Do analysts recommend ALEC or TRML? Alector presently has a consensus price target of $3.83, indicating a potential upside of 19.42%. Tourmaline Bio has a consensus price target of $45.65, indicating a potential downside of 4.72%. Given Alector's higher possible upside, equities research analysts plainly believe Alector is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 3 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.82Tourmaline Bio 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals have more ownership in ALEC or TRML? 85.8% of Alector shares are owned by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are owned by institutional investors. 9.7% of Alector shares are owned by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryTourmaline Bio beats Alector on 8 of the 14 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$335.01M$3.47B$6.23B$10.67BDividend YieldN/A2.27%5.74%4.88%P/E Ratio-2.7723.0629.1527.23Price / Sales3.23497.06588.88131.98Price / CashN/A47.5937.5161.65Price / Book2.4910.6612.326.59Net Income-$119.05M-$52.56M$3.32B$276.14M7 Day Performance0.63%2.64%0.73%-0.72%1 Month Performance0.94%13.86%7.27%2.47%1 Year Performance-31.70%14.85%61.92%33.90% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.9427 of 5 stars$3.21-3.0%$3.83+19.4%-30.4%$335.01M$100.56M-2.77270Trending NewsAnalyst DowngradeGap DownHigh Trading VolumeTRMLTourmaline Bio1.6768 of 5 stars$47.90flat$45.65-4.7%+69.3%$1.23BN/A-13.9644Positive NewsShort Interest ↓NBTXNanobiotix0.8494 of 5 stars$25.60-3.7%$11.00-57.0%+370.3%$1.23B$39.18M0.00100Gap DownHigh Trading VolumeMAZEMaze Therapeutics2.3716 of 5 stars$27.81-2.2%$33.83+21.7%N/A$1.22B$167.50M0.00121Short Interest ↑ARDXArdelyx4.2839 of 5 stars$5.03-0.4%$11.70+132.6%-10.0%$1.21B$333.61M-21.8790CVACCureVac3.5299 of 5 stars$5.36-0.2%$6.83+27.5%+93.9%$1.20B$579.18M5.58880IMTXImmatics2.9453 of 5 stars$9.87-3.2%$13.67+38.5%+9.5%$1.20B$168.65M-15.18260SANASana Biotechnology2.8289 of 5 stars$5.03-5.1%$7.50+49.1%+45.3%$1.20BN/A-4.75380PGENPrecigen4.291 of 5 stars$4.00+14.6%$8.25+106.3%+340.0%$1.19B$3.92M-9.52190High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180NUVBNuvation Bio2.2701 of 5 stars$3.41-6.1%$7.86+130.4%+78.2%$1.17B$7.87M-5.4160 Related Companies and Tools Related Companies Tourmaline Bio Alternatives Nanobiotix Alternatives Maze Therapeutics Alternatives Ardelyx Alternatives CureVac Alternatives Immatics Alternatives Sana Biotechnology Alternatives Precigen Alternatives Calliditas Therapeutics AB (publ) Alternatives Nuvation Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
